208
Participants
Start Date
July 26, 2024
Primary Completion Date
July 26, 2027
Study Completion Date
December 5, 2027
Pulmonary vein isolation
The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
DC Cardioversion
DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
Implantable loop recorder
The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
Femoral sheath insertion
Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
RECRUITING
Barts Heart Centre, London
Barts & The London NHS Trust
OTHER